Clinical Trials Sponsored by Cellular Sciences, inc.

Total 1450 results

Emphycorp
Cellular Sciences, inc.

Completed

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

Cystic Fibrosis

United States
Emphycorp
Cellular Sciences, inc.

Completed

Sodium Pyruvate Therapy in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
University of Minnesota
Cellular Sciences, inc.

Terminated

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

Cystic Fibrosis

United States
Intra-Cellular Therapies, Inc.

Recruiting

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar Disorder

United States
Intra-Cellular Therapies, Inc.

Recruiting

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Parkinson Disease

United States
Intra-Cellular Therapies, Inc.

Active, not recruiting

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Schizophrenia

United States, Poland, Bulgaria, Serbia
Intra-Cellular Therapies, Inc.

Enrolling by invitation

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Germany, Hungary, Poland, Finland, India, Korea, Republic of, Sweden
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Bipolar Depression

Russian Federation, Ukraine, United States, Bulgaria, Serbia
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Bipolar Depression | Major Depressive Disorder

United States, Bulgaria, Russian Federation, Serbia, Ukraine
Intra-Cellular Therapies, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Pediatric

United States
Mynosys Cellular Devices, Inc.

Completed

A Prospective Multi-Center Study of Anterior Lens Capsulotomy Using the Mynosys Zepto System

Cataract
Intra-Cellular Therapies, Inc.

Completed

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Schizophrenia

United States
Cellular Sciences, inc.
Family First Medical Research Center

Recruiting

The Effect of N115 on Coughing in IPF Patients

Idiopathic Pulmonary Fibrosis

United States
Intra-Cellular Therapies, Inc.

Recruiting

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Intra-Cellular Therapies, Inc.

Not yet recruiting

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

Bipolar Disorder, Manic

United States
Intra-Cellular Therapies, Inc.

Completed

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Germany, Poland, Finland, Sweden, Argentina
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Hungary, India
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Agitation in Dementia, Including Alzheimer's Disease

United States
Intra-Cellular Therapies, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Heart Failure, Systolic

United States
Intra-Cellular Therapies, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Parkinson Disease

United States
Intra-Cellular Therapies, Inc.

Completed

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Alzheimer's Disease

United States
Intra-Cellular Therapies, Inc.

Completed

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

Schizophrenia

United States
Intra-Cellular Therapies, Inc.

Completed

Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

Schizophrenia

United States
Intra-Cellular Therapies, Inc.

Recruiting

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Bipolar Disorder, Manic

United States
Intra-Cellular Therapies, Inc.

Recruiting

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Bipolar Depression

United States
Intra-Cellular Therapies, Inc.

Recruiting

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Healthy Volunteers

United States
Intra-Cellular Therapies, Inc.

Recruiting

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Innovative Cellular Therapeutics Inc.

Recruiting

GCC19CART for Patients With Metastatic Colorectal Cancer (CARAPIA-1)

Colorectal Cancer

United States
Intra-Cellular Therapies, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

Schizophrenia

United States
Intra-Cellular Therapies, Inc.

Completed

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Bipolar Depression

United States, Russian Federation, Ukraine, Bulgaria, Serbia, Colombia
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Bipolar Depression

United States
Intra-Cellular Therapies, Inc.

Completed

A Trial to Assess the Antipsychotic Efficacy of ITI-007

Schizophrenia

United States
Takeda
Intra-Cellular Therapies, Inc.

Terminated

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Schizophrenia

United States
University of Chicago
Intra-Cellular Therapies, Inc.

Recruiting

Caplyta in Borderline Personality Disorder

Borderline Personality Disorder

United States
Intra-Cellular Therapies, Inc.
Laureate Institute for Brain Research, Inc.

Completed

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement

Healthy Volunteers

United States
Halucenex Life Sciences Inc.
KGK Science Inc.

Active, not recruiting

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Post Traumatic Stress Disorder | Treatment Resistant Disorders

Canada
University of Massachusetts, Worcester
Intra-Cellular Therapies, Inc.

Recruiting

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

Schizophrenia | Schizo Affective Disorder

United States
New York State Psychiatric Institute
Intra-Cellular Therapies, Inc.

Terminated

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Schizophrenia

United States
USANA Health Sciences
KGK Science Inc.

Completed

Effect of a MVM Dietary Supplement on Indices of Human Health

Metabolic Syndrome

Canada
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Healthy Volunteers

United States
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Healthy Volunteers

United States
SK Life Science, Inc.
PRA Health Sciences

Completed

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Healthy Subjects

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

Healthy Volunteers

United States
Cellular Sciences, inc.
Missouri State University; Dynamic DNA Labs; Trinity Health Care; Family First...

Completed

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

Long COVID

United States
Cellular Sciences, inc.
Missouri State University; Dynamic DNA Labs; Trinity Health Care; Family First...

Completed

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

COVID-19

United States
Integrative Skin Science and Research
AgeLess Sciences Inc.

Active, not recruiting

The Effects of a Longevity Supplement on Aging and Photoaging

Photoaging

United States
Dana-Farber Cancer Institute
Celula, Inc.

Terminated

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Sight Sciences, Inc.

Not yet recruiting

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Pseudophakic Eyes (EVOLVE)

Primary Open Angle Glaucoma

United States
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)

Wet Age-related Macular Degeneration

United States, Puerto Rico

Clinical Trials Sponsored by Cellular Sciences, inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations